Source link : https://www.newshealth.biz/health-news/imlunestrant-shows-pfs-benefit-in-advanced-breast-cancer/
SAN ANTONIO — Second-line treatment with imlunestrant improved progression-free survival compared with standard endocrine monotherapy in patients with advanced estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who had ESR1 mutations, according to recent findings from the EMBER-3 trial. This progression-free survival benefit with imlunestrant did not extend to the overall […]
Author : News Health
Publish date : 2024-12-13 11:50:21
Copyright for syndicated content belongs to the linked Source.